Medindia

X

Iodex goes to SmithKline Beecham consumer Healthcare

by Medindia Content Team on  December 24, 2001 at 12:03 PM Drug News   - G J E 4
Iodex goes to SmithKline Beecham consumer Healthcare
Iodex is the market leader in the pain-balm segment, with a market share of 70 per cent-plus. Iodex faces challenges from local brands like Amrutanjan, Tiger Balm (locally manufactured by Elder Pharma), Zandu Balm and Sensur of Glenmark.
Advertisement

Glaxo SmithKline India (GSK) has decided to transfer its Iodex range of products to SmithKline Beecham Consumer Healthcare (SKBCH), a GSK subsidiary. SKBCH has a strong marketing and distribution network in India, comprising over 1,600 wholesalers and direct coverage of over 4,00,000 retail outlets.

Advertisement
Last year, Glaxo India and SmithKline Beecham Pharmaceutical India had merged and it was announced that the focus of the merged entity, GSK, would give more focus on prescription drugs and vaccines rather than over-the-counter (OTC) products. The officials said with this transfer of the Iodex brand, the entire promotion, marketing and distribution will be carried out by SKBCH, a leading player in the OTC segment.

The Iodex brand was owned by SmithKline Beecham Plc, the British parent, and had been licensed to SmithKline Beecham Pharmaceuticals India. Iodex has a turnover of around Rs 100 crore, and analysts say it could be valued at Rs 300 crore. The pain-and-rub market in India is currently valued in the Rs 350-400 crore range.
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All